Skip to content
CDMO SERVICES FOR VIRAL VECTORS & VACCINES

(GMP) Manufacturing

Ensure your viral vector reaches its full potential. 

Our extensive expertise attained over years of specializing in virus development and GMP manufacturing guides the process, from early discussions about your product to preparing detailed batch documentation up to the final production and release of (pre)clinical batches. Our workflow is focused on transparency, safety, and effectiveness. 

IN A NUTSHELL

Preclinical and GMP-Compliant Manufacturing for Viral Vectors and Vaccines

Our viral vector GMP manufacturing services follow an open-source concept, including state-of-the-art technologies, to ensure robust and scalable production processes, which meet the highest product quality requirements. 

We are able to provide processes for our various vector platforms (LV, AAV, AV & MVA) as well as Process Development and production for any customer derived platform in our brand-new biosafety level 2 QC labs and GMP facility up to 200L. 

Viral Services Infographic GMP Manufacturing
HOW WE WORK

Across the Entire GMP Life Cycle 

Our services comprise everything from the start of your viral vectors GMP life cycle. We start with the generation of your MCB and/or MVS, either from your cell line or vector platform or one of our established MCBs or vector platforms. With quality assurance and control integrated into the project team, we monitor and test the quality of your product every step of the way until the vial is ready for your (pre)clinical studies. 

GMP Compliance 

We generate efficient and optimized manufacturing processes. Our focus is on product and patient safety, which is why we adhere strictly to the prescribed GMP guidelines. To perpetuate the quality of our products we have a strict QMS in place. Annex 1 serves as a leading guideline, particularly with regard to the generation of sterile medicinal products.

 

Capability and Scale

Our newly built state-of-the-art clean room houses bioreactors up to 200L for the upstream process and numerous dead-end filtration, TFF, and chromatography devices for the downstream process, which is more than sufficient for your clinical studies. We could use either stable producer cell lines or transfection to produce your final product. Once the drug substance has been produced, we can manufacture your drug product in-house.

Drug Product Filling 

At the end of the value chain, the drug substance is refined into a drug product. Our filling process is based on a semi-automated solution (robotic support) in a class A clean room environment to ensure aseptic conditions. We are capable of aseptically filling the drug product and required diluents into 2, 6- and 20-mL vials with a throughput of approx. 200-400 vials per hour. Our sterile production fulfills the necessary Annex 1 requirements. 

State-of-the-Art Technologies 

From upstream processing to downstream purification of your product with state-of-the-art, single-use systems for dead-end filtration, tangential flow filtration, or chromatographic purification and final aseptic filling, our aim is to always support our customers with cutting-edge technologies. 

All in One Place 

Our QC team is housed next to the GMP suite for efficient and fast measurements. Thus, short distances between our production facility and the quality control laboratories ensure optimal handling and analysis of sensitive viral products and intermediates.

HOW WE WORK

Across Whole Viral Vectors GMP Life Cycle

GMP-Compliance

Capability and Scale

State-of-Art Technologies

Drug Product Filling

All on One Place

Our Promise To You

Asset 9
 
Regulatory Support
  • Navigate regulatory requirements to secure compliance with global regulatory agencies 
  • Provide comprehensive support to facilitate regulatory submissions and approvals, incl. regulatory documentation 
  • Conduct risk assessments
Asset 12
 
Fully Disposable Processes
  • Fully disposable upstream, downstream, and filling processes 
  • Flexible management of complex processes and products 

 

 

 

Asset 1
 
Annex 1 Compliance
  • Compliance with Annex 1 requirements for sterile drug product manufacturing 
  • Aseptic production in closed systems 
  • Fill and finish process covers a full inspection of vial integrity  

 

 

Elevate Your Candidate With The Right CDMO

Discover Related Services

Explore Viral Technologies

Explore Related Content

Header CDMO

Trends and Requirements in CDMO Projects for Biopharmaceuticals

Blog Post

Blog Image-09-1

Transponsons and Transposases: A Dynamic Duo in Genetic Engineering

Blog Post

COVER Process Intensification Blogpost-16by9 (1)-1

Investing in Efficiency: Benefits of Process Intensification in Upstream Processing

Blog Post

Interim Header Picture

A Success Story on Partnership - the Invisible Superpower in CDMO Projects

Blog Post

Newsletter
Join for ProBioGen News - make sure to be always up-to-date and fully informed with our latest company announcements.